(RU2612061) Randomized Phase II Study of AB (nab-paclitaxel [Abraxane], Bevacizumab) versus Ipilimumab for 1st Line Therapy of Unresectable Stage IV Metastatic Malignant Melanoma (BRAF V600E Negative)
Description: 

To assess whether the combination nab-paclitaxel and bevacizumab (AB) prolongs progression-free status relative to ipilimumab as a 1st line treatment in patients with unresectable stage IV melanoma.

Study Number: 

I 244013

Phase: 
II
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT01879306

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.